Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02493738
Other study ID # BR-ITR-CT-101
Secondary ID
Status Completed
Phase Phase 1
First received July 7, 2015
Last updated March 3, 2016
Start date July 2015
Est. completion date October 2015

Study information

Verified date March 2016
Source Boryung Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry of Food and Drug Safety
Study type Interventional

Clinical Trial Summary

Study Objectives:

- To evaluate the pharmacokinetics (PK) of orally administered Lozanoc under fasted and fed condition in healthy male subjects

- To compare the pharmacokinetics (PK) of orally administered Lozanoc and Sporanox under fed condition in healthy male subjects

- To evaluate the safety and tolerability of single oral dose of Lozanoc and Sporanox in Korean healthy male subjects


Description:

Phase I Study divided into 3 parts written as bellows.

Part I. Lozanoc 50mg single dose under fed condition vs Part 2. Lozanoc 50mg single dose under fasted condition vs Part 3. Sporanox 100mg single dose under fed condition


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 50 Years
Eligibility Inclusion Criteria:

1. Korean male volunteers in the age between 19 and 50 years old (inclusive)

2. Subject who are able to give signed informed consent

3. Body mass index (BMI) in the range of 19 to 28 kg/m2 and weighting at least 50kg

4. Subject who are considered

- Pre-study physical examination with no clinically significant abnormalities

- No clinically significant medical history

- Vital signs were to be within reference ranges, or if outside of the range, not deemed clinically significant in the opinion of the Investigator

- 90 mmHg = systolic blood pressure (sitting position) = 140mmHg

- 50 mmHg = diastolic blood pressure (sitting position) = 90 mmHg

- Pre-study clinical laboratory findings were to be within reference range, or if outside of the range, not deemed clinically significant in the opinion of the Investigator

- No clinically significant abnormalities in 12-lead ECG results

5. Agree to continue to use at least two accepted methods of birth control and not to donate sperm for at least 1 days before the first dosing, during the course of the study and for a period of 90days following the last dosing.

- Acceptable methods of birth control are: female (sexual partner) hormonal contraceptives; intrauterine device; surgical sterility at least 6 months prior to screening (Ex. hysterectomy, bilateral oophorectomy, and/or tubal ligation); use diaphragm; use condom; or spermicide

Exclusion Criteria:

Subjects will be excluded if they meet any of the following criteria:

1. History of allergy or sensitivity to any drug, including any prior serious adverse reaction to antifungal agent(s)

2. History of congestive heart failure or Patients with ventricular dysfunction such as congestive heart failure

3. Undergone surgery or who have a medical condition, that in the judgment of the Investigator, may affect absorption, distribution, metabolism or elimination of the drug product

4. Participated in a previous clinical trial within 90 days prior to screening visit

5. Donated blood or had a significant loss of blood within 60 days prior to screening visit

6. Special diet or substantial changes in eating habits within 30 days prior to screening visit

7. Use of any prescription medication within 14 days before screening visit

8. Use of any other OTC medication within the 7 days before screening visit

9. History of smoking within 3 months prior to screening visit

10. Have a recent history (within 2 years prior to the screening visit) of alcohol or drug abuse or a positive screen for drugs of abuse at screening

11. Positive blood screen for HIV or hepatitis B or C or syphilis

12. Clinically important abnormal hepatic function test (AST, ALT greater than 2 fold of reference upper limit (ULN), or total bilirubin greater than 1.5 x ULN)

13. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label


Intervention

Drug:
Lozanoc 50mg
Lozanoc 50mg single dose under fed and fasted condition
Sporanox 100mg
Sporanox 100mg single dose under fed condition

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax 0~120 hour after medication Yes
Secondary tmax 0~120 hour after medication Yes
Secondary AUCinf 0~120 hour after medication Yes
See also
  Status Clinical Trial Phase
Terminated NCT01982071 - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Phase 4
Completed NCT02391532 - Effect of Probiotic Bacteria on Oral Candida in Frail Elderly N/A
Completed NCT01447407 - Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine Phase 1
Not yet recruiting NCT00889356 - Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Phase 3
Completed NCT00105144 - Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Phase 3
Completed NCT00163111 - A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. Phase 3
Completed NCT00138502 - Funguria in Hospitalized Patients
Not yet recruiting NCT04502277 - Bioavailability of Flucanazole Early Phase 1
Completed NCT03203551 - Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous. N/A
Completed NCT05044156 - Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
Completed NCT01322698 - Staging Candidiasis in ICU Patients N/A
Terminated NCT01092832 - A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients Phase 3
Terminated NCT00095316 - Caspofungin Study for Fungal Infections in Adults in Critical Care Settings Phase 3
Completed NCT04122560 - Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration Phase 4
Completed NCT02641717 - Validity of Patient-Collected Wet Mounts N/A
Recruiting NCT01253954 - A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China N/A
Completed NCT00734539 - Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight Phase 3
Completed NCT00797420 - Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers Phase 1
Completed NCT00001937 - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Phase 3
Completed NCT02666716 - Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients